Response to chemotherapy with benznidazole of clones isolated from the 21SF strain of Trypanosoma cruzi (biodeme Type II, Trypanosoma cruzi II).
Susceptibility to chemotherapy with benznidazole was investigated of 5 clones isolated from the 21 SF strain (biodeme Type II, Trypanosoma cruzi II). Swiss mice were infected with the parental strain for each clone and submitted to chemotherapy with benznidazole (100mg/kg/day during 90 days). Treatment determined negativity of the parasitemia. Cure rates were evaluated by parasitological cure tests. Serology was evaluated for treated animals (titers from negative to 1:640) and untreated controls (1:160 to 1:640). Cure rates varied from 30 to 100% for the 5 clones, and were 25% for the parental strain. Results suggested that the variability of response to treatment of the clonal populations of Trypanosoma cruzi II strains is responsible for the high variation in the response to chemotherapy with benznidazole and nifurtimox by strains of this biodeme.
Campos
Rozália Figueira
RF
Laboratório de Chagas Experimental, Autoimunidade e Imunidade Celular, Centro de Pesquisas Gonçalo Moniz, Fundação Oswaldo Cruz, Salvador, BA, Brasil.
Guerreiro
Marcos Lázaro S
ML
Sobral
Karina de Souza Castro
Kde S
Lima
Rita de Cássia P Cunha
Rde C
Andrade
Sonia G
SG
D000818:Animals; D014355:Chagas Disease / Q000188:drug therapy* / Q000469:parasitology; D051379:Mice; D009593:Nitroimidazoles / Q000627:therapeutic use*; D018512:Parasitemia / Q000188:drug therapy; D013997:Time Factors; D014344:Trypanocidal Agents / Q000627:therapeutic use*; D014349:Trypanosoma cruzi / Q000187:drug effects* / Q000235:genetics
D009593:Nitroimidazoles; D014344:Trypanocidal Agents; C009999:benzonidazole